Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 714 in Celiac Disease
NCT02637141Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ordesekimab in celiac disease, sponsored by Amgen. Started Apr 2016; status: completed.
02
Drugs
ordesekimab
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT02637141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637141.